Swedish Orphan Biovitrum AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

26.02.18	Henrik Stenqvist is Joining Sobi™ as New Chief Financial Officer (PR Newswire)
23.02.18	Kineret® (anakinra) Receives a Positive Opinion from CHMP for the Treatment of Still's Disease (PR Newswire)
13.02.18	Invitation - Presentation of Sobi's Q4/FY 2017 Results (PR Newswire)
07.02.18	Time to Elevate Protection in Haemophilia Care: New Data From Sobi™ (PR Newswire)
07.02.18	The Republic of Ireland Switches all People With Haemophilia A & B Treated With Replacement Clotting Factors to Sobi's™ Extended Half-life Therapies (PR Newswire)
23.01.18	FDA Accepts Investigational New Drug Application and Grants Fast Track Status for SOBI003 for the Treatment of MPS IIIA (PR Newswire)
04.01.18	Global Gas Insulated Substation Market to 2025 - Demand for More Reliable, Long Life Span and Less Maintenance Systems (PR Newswire)
16.11.17	Sobi™ - First Patient Randomised in a Phase 3 Study Evaluating Safety and Efficacy of Anakinra in the Treatment of Still's Disease (PR Newswire)
27.10.17	The First Patient Enrolled in the ReITIrate Study Evaluating Immune Tolerance Induction With Elocta® (PR Newswire)
25.10.17	Sobi: Alprolix® Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia B (PR Newswire)
24.10.17	Sobi™ Establishes New Leadership Structure and Appoints Torbjörn Hallberg as General Counsel (PR Newswire)
06.10.17	Norbert Oppitz Joins Sobi™ as New Senior Vice President, Specialty Care (PR Newswire)
05.09.17	Sobi Receives Approval From the FDA for Once-daily Dosing Frequency of Orfadin® for the Treatment of HT-1 (PR Newswire)
06.07.17	Invitation - Presentation of Sobi's Q2 2017 Results (PR Newswire)
30.06.17	Xiapex® Gets Recommendation to be Made Available on National Health Service in England (PR Newswire)
27.06.17	EMA Approves the Potential to Dose Every 14 Days or Longer in Updated Dosing Regimen for Alprolix® (PR Newswire)
26.06.17	Elekta Chooses Brainlab to Distribute Stereotactic Neurosurgical Solutions Within Selected Markets in Europe (PR Newswire)
05.06.17	Sobi™ Keeps the Partner Products Business Area as an Integral Part of the Company (PR Newswire)
31.05.17	Sobi™ Discloses Payments to the Healthcare Professionals and Healthcare Organisations to Increase Transparency (PR Newswire)
18.05.17	Swedish Orphan Biovitrum AB - Elocta® Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia A (PR Newswire)
17.05.17	Swedish Orphan Biovitrum AB - Orfadin® Capsules Approved in the Kingdom of Saudi Arabia for the Treatment of Hereditary Tyrosinemia Type 1 (PR Newswire)
03.05.17	Sobi Opens Office in Greece (PR Newswire)
13.04.17	Invitation - Presentation of Sobi's Q1 2017 Results (PR Newswire)
07.03.17	Swedish Orphan Biovitrum AB - FDA Approves in-use Storage at Room Temperature for Orfadin® Capsules (PR Newswire)
21.02.17	Sobi™ Enters Into new Distribution Agreement With Valeant for Ammonul® (PR Newswire)
03.02.17	Swedish Orphan Biovitrum AB - Invitation - Presentation of Sobi's Q4 and FY 2016 Results (PR Newswire)
02.02.17	Swedish Orphan Biovitrum AB - Long-term Safety and Efficacy Data of Extended Half-life Therapy Alprolix in Children With Haemophilia B Published in The Lancet Haematology (PR Newswire)
02.02.17	Sobi Obtains Approval From the European Commission for new Dosing Frequency of Orfadin® (PR Newswire)
01.02.17	Sobi and Bioverativ to Reveal new Long-term Safety and Efficacy Data of Elocta® and Alprolix® at EAHAD (PR Newswire)
19.01.17	Swedish Orphan Biovitrum AB: First Patients Enrolled in 24 Month Real-world Study Evaluating Effectiveness of Elocta® (PR Newswire)
07.12.16	Sobi and Horizon Pharma enter five-year distribution agreement for Ravicti® and Ammonaps® outside the United States (PR Newswire)
21.11.16	Swedish Orphan Biovitrum AB: Elocta® Approved in Kuwait for the Treatment of Haemophilia A (Businesswire)
14.11.16	Swedish Orphan Biovitrum AB: European Study of Real-Life Haemophilia Treatment Emphasizes Need to Improve Standard of Care (Businesswire)
28.10.16	Swedish Orphan Biovitrum AB: Alprolix® Approved in Switzerland for the Treatment of Haemophilia B (Businesswire)
27.10.16	Swedish Orphan Biovitrum AB: Sobi™ Publishes Its Report for the Third Quarter 2016, Raises Guidance (Businesswire)
19.10.16	Swedish Orphan Biovitrum AB: European Commission Grants SOBI003 Orphan Designation for the Treatment of MPS IIIA (Businesswire)
13.10.16	Swedish Orphan Biovitrum AB: Invitation – Presentation of Sobi’s third quarter results 2016 (Businesswire)
03.10.16	Swedish Orphan Biovitrum AB: European Commission Approves Transfer of Marketing Authorisation for Alprolix® to Sobi™ (Businesswire)
26.09.16	Swedish Orphan Biovitrum AB: Alprolix® Obtains Reimbursement across the United Kingdom (Businesswire)
26.09.16	Swedish Orphan Biovitrum AB: Milan Zdravkovic joins Sobi as Senior Vice President, Head of Research & Development (Businesswire)
23.09.16	Swedish Orphan Biovitrum AB: Elocta® Obtains National Reimbursement in Spain, Now Available in the Five Largest Markets in the EU (Businesswire)
21.09.16	Swedish Orphan Biovitrum AB: Elocta® obtains reimbursement in UK, Italy and France, complemented by real-world data and extensive patient experience (Businesswire)
31.08.16	New Number of Shares and Votes in Swedish Orphan Biovitrum AB (publ) (Businesswire)
08.08.16	Swedish Orphan Biovitrum AB: Sobi’s CEO divests a portion of shares (Businesswire)
15.07.16	Swedish Orphan Biovitrum AB: Sobi's Board of directors exercises its authorisation for repurchase of shares to secure the company’s commitments under the incentive programme (Businesswire)
15.07.16	Swedish Orphan Biovitrum AB: Sobi Publishes Its Report for the Second Quarter 2016 (Businesswire)
14.07.16	Swedish Orphan Biovitrum AB: Health Canada Validates Orfadin® Capsule Filing (Businesswire)
27.06.16	Swedish Orphan Biovitrum AB: Sobi’s Elocta® (rFVIIIFc) Approved in Switzerland for the Treatment of Haemophilia A (Businesswire)
15.06.16	Swedish Orphan Biovitrum AB: Orfadin® 20 mg capsule approved in the US (Businesswire)
06.06.16	Swedish Orphan Biovitrum AB: Sobi: First Alprolix® Sales in the EU (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Geberit	523.00	1.24 %	K V
Part Grp Hldg	1’243.00	1.22 %	K V
Roche Hldg G	253.90	1.12 %	K V
Sonova Hldg	306.90	0.95 %	K V
Novartis	92.34	0.85 %	K V
Givaudan	3’931.00	0.31 %	K V
Kuehne+Nagel Int	208.40	0.19 %	K V
Zurich Insur Gr	548.40	0.15 %	K V
Swiss Life Hldg	728.00	0.11 %	K V
Nestle	76.02	0.08 %	K V

Nachrichten zu Swedish Orphan Biovitrum AB

Aktien Top/Flop

Meistgelesene Nachrichten